The increasing prevalence of inflammatory bowel disease and the high costs associated
with biologic therapies suggest that biologics with lower costs, but no compromise on …

With the expiration of patent protection for several biologics looming, the production of highly
similar therapeutic agents has begun to emerge on the pharmaceutical market. These …

Biosimilars are biologic products that are highly similar, but not identical, to a licensed
reference (or" originator") biologic product. These agents have the potential to provide …

Objectives To assess the degree of readability and the length of the package leaflets of
biosimilars. Setting The package leaflets analysed were downloaded from the European …

(1) Background: A biosimilar is a biologic medical product that has been approved by the
United States Food and Federal Drug Administration (FDA) and is an almost identical copy …

In oncology practices across the United States, biosimilars—highly similar versions of
licensed, innovator (reference) biological medicines—are currently emerging as more …

The emergence of therapeutically effective biological agents has been a major breakthrough
for the management of a wide range of chronic diseases with problematic, delayed or even …

Biosimilars are biological products that are highly similar to regulatory approved biological
products or “innovator” products, which are also known as reference products [1, 2] …